New York, November 20th, 2018 Based on the exclusive “DrugLnk” organic synthesis platform, Creative Biolabs develops Ipatasertib linker complexes using readily available or customized linkers for antibody conjugation in a timely and cost-effective manner.
As a regulator for a number of biological processes, Akt is a serine/threonine-specific protein kinase that plays a key role in the PI3K/Akt pathway. The activated Akt is capable of contributing to tumor anti-apoptotic activities and regulating cell cycle progression. Ipatasertib, also known as GDC-0068, is a strong ATP-competitive pan-AKT inhibitor, which shows a powerful inhibition of all protein kinase B (Akt) isoforms but a weak suppression towards other members of the protein kinase family. For the treatment of both tumor xenograft mouse models and human cancer cell lines, ipatasertib showed a significant suppression of Akt signaling, bringing a disruption in cell cycle progression and reduced cancer cell viability.
“As a highly selective and specific Akt inhibitor, ipatasertib not only exhibits dose-dependent inhibition of Akt signaling and potent antitumor activity, but also shows distinguished level of activities in cells with and without activated Akt signaling, making it an excellent choice as a new anti-cancer therapeutic agent” Said an expert in Creative Biolabs.
“Composed of cytotoxic agents conjugated to monoclonal antibodies, antibody-drug conjugates (ADCs) can target antigens differentially overexpressed on tumor cells. Due to its potent cytotoxicity, ipatasertib is considered to be a promising cytotoxic payload for the construction of ADCs. Our team can provide tailored strategies for antibody-drug conjugates (ADCs) and other targeted antibody therapeutics development by ipatasertib (GDC-0068) and derivatives as payloads to treat a wide range of tumor models and cancer cell lines.”
With rich experience and an advanced platform, Creative Biolabs can customize numerous cytotoxic agents for ADC engineering to meet a variety of specific needs of both industrial and academic clients. Meanwhile, other tailored services related to antibody-drug conjugate development are also available in Creative Biolabs owing to its one-stop ADC development platform.
About Creative Biolabs
Creative Biolabs has established our leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. We offer our customers with comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation. Furthermore, our inventory also contains an extensive list of linkers, payloads, payload-linker sets, and commonly used ADCs for quick deployment and concept validation.
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States